Published on

Medicine – Haemophilia A (Classical Haemophilia)

Haemophilia A is an inherited bleeding disorder caused by a deficiency or dysfunction of coagulation factor VIII (FVIII). It causes defective secondary haemostasis, resulting in prolonged bleeding, particularly into joints and muscles.

Haemophilia A is the most common form of haemophilia and is inherited predominantly as an X-linked recessive disorder.

Important Clinical Principle

Haemophilia A typically causes deep tissue bleeding and haemarthroses, rather than the superficial petechiae and mucocutaneous bleeding characteristic of platelet disorders.

1. Aetiology and Genetics

  • Deficient factor: Factor VIII.
  • Gene involved: F8 gene on the X chromosome (Xq28).
  • Inheritance: X-linked recessive.
  • Affected individuals: Predominantly males, although female carriers may have reduced factor VIII activity and clinically significant bleeding.
  • Alternative name: Classical haemophilia.
  • Family history: May be absent because of a new mutation.

2. Pathophysiology

Factor VIII is an essential cofactor in the intrinsic coagulation pathway.

Activated factor VIII (FVIIIa) combines with activated factor IX (FIXa) to form the intrinsic tenase complex, which activates factor X.

Factor VIII deficiency therefore reduces factor X activation, thrombin generation and fibrin clot formation.

Illustration: Pathophysiology of Haemophilia A

Factor VIII Deficiency Haemophilia A Impaired Intrinsic Tenase Reduced FIXa–FVIIIa activity Reduced Factor X Activation Reduced Thrombin Generation Impaired Fibrin Clot Formation Defective secondary haemostasis Deep Tissue and Joint Bleeding

3. Clinical Features

Haemophilia A often presents in infancy or early childhood, particularly following trauma, circumcision or surgery. Severe disease may cause spontaneous bleeding.

A. Joint Bleeding (Haemarthrosis)

  • Commonly affects the knees, ankles and elbows.
  • Causes joint pain, swelling, warmth and restricted movement.
  • Recurrent bleeding can lead to chronic haemophilic arthropathy.
  • Long-standing disease may cause joint deformity and disability.

B. Muscle Bleeding

  • Deep muscle haematomas.
  • Iliopsoas haemorrhage.
  • Possible nerve compression.
  • Compartment syndrome in severe cases.

C. Other Bleeding Manifestations

  • Prolonged bleeding following trauma.
  • Excessive bleeding after surgery or dental extraction.
  • Intracranial haemorrhage.
  • Haematuria.
  • Gastrointestinal bleeding in severe cases.
Examination Point: Haemophilia produces deep tissue and joint bleeding, whereas platelet disorders and von Willebrand disease predominantly cause mucocutaneous bleeding.

4. Classification According to Severity

Severity Factor VIII Activity Clinical Presentation
Severe <1% Frequent spontaneous joint and muscle bleeding
Moderate 1–5% Bleeding after minor trauma; occasional spontaneous bleeding
Mild >5% to <40% Bleeding mainly after significant trauma, surgery or dental procedures

Severity is classified according to baseline factor VIII activity, although clinical bleeding patterns may vary.

5. Laboratory Findings

Investigation Typical Result
Prothrombin time (PT)Normal
Activated partial thromboplastin time (aPTT)Often prolonged
Thrombin time (TT)Normal
Platelet countNormal
FibrinogenNormal
Factor VIII activityReduced
Factor IX activityUsually normal
Important Clarification: A normal aPTT does not exclude mild haemophilia A. A specific factor VIII activity assay is required for confirmation.

6. Diagnosis

  1. Clinical history of recurrent joint or deep tissue bleeding.
  2. Family history suggestive of X-linked inheritance.
  3. Coagulation screening tests, particularly PT and aPTT.
  4. Specific factor VIII activity assay to confirm deficiency and determine severity.
  5. Genetic testing of the F8 gene when indicated.

A mixing study may help distinguish factor deficiency from an inhibitor when the aPTT is prolonged.

Von Willebrand disease, particularly type 2N, may also cause reduced factor VIII activity and should be considered in the differential diagnosis.

Diagnostic Flowchart

Suspected Haemophilia Haemarthrosis / deep bleeding Coagulation Screening PT normal; aPTT often prolonged Specific Factor Assays Measure factor VIII and IX activity Reduced Factor VIII Activity Factor IX usually normal Haemophilia A Confirmed Classify severity and plan treatment

7. Management of Haemophilia A

Management depends on bleeding severity, baseline factor VIII activity, inhibitor status and available therapies.

A. Minor Bleeding

  • Local pressure and appropriate supportive measures.
  • Rest, ice, compression and elevation for selected musculoskeletal injuries, without delaying haemostatic treatment.
  • Desmopressin (DDAVP) in selected patients with mild haemophilia A who have demonstrated an adequate response.
  • Tranexamic acid for selected mucosal bleeding episodes.

Desmopressin increases circulating factor VIII by stimulating endothelial release of factor VIII and VWF.

It is not sufficient for severe haemophilia A and requires precautions against fluid retention and hyponatraemia.

B. Major Bleeding

Major bleeding, including significant haemarthrosis, deep muscle haemorrhage and intracranial haemorrhage, requires urgent haemostatic treatment.

  • Factor VIII concentrate for patients without inhibitors.
  • Prompt assessment and management of the bleeding site.
  • Specialist management if factor VIII inhibitors are present.
  • Rehabilitation and physiotherapy after acute joint bleeding is controlled.
Emergency Warning: Suspected intracranial or other life-threatening haemorrhage requires immediate specialist-directed haemostatic treatment without waiting for confirmatory imaging.

C. Long-Term Prophylaxis

  • Regular factor VIII replacement, including extended-half-life preparations.
  • Emicizumab prophylaxis in appropriate patients.
  • Physiotherapy and joint protection.
  • Regular screening for factor VIII inhibitors.
  • Gene therapy may be considered in selected eligible patients according to local availability.

Emicizumab is a bispecific antibody that mimics the cofactor function of factor VIII. It is used for prophylaxis, but not as sole treatment for acute major bleeding.

Treatment Flowchart

Haemophilia A Assess bleeding severity Minor Bleeding Selected mild cases Major Bleeding Urgent treatment Supportive Measures Pressure / rest / elevation DDAVP if responsive Tranexamic acid if suitable Haemostatic Therapy Factor VIII replacement Assess inhibitor status Urgent specialist care Long-Term Prevention Prophylaxis, joint care, inhibitor monitoring

8. Haemophilia A Versus Haemophilia B

Feature Haemophilia A Haemophilia B
Deficient factorFactor VIIIFactor IX
Alternative nameClassical haemophiliaChristmas disease
InheritanceX-linked recessiveX-linked recessive
Clinical presentationJoint and muscle bleedingJoint and muscle bleeding
PTNormalNormal
aPTTOften prolongedOften prolonged
Platelet countNormalNormal
DiagnosisLow factor VIII activityLow factor IX activity
Replacement therapyFactor VIIIFactor IX
DDAVPMay help selected mild casesIneffective

9. High-Yield Examination Summary

Aspect Important Point
Alternative nameClassical haemophilia
Deficient factorFactor VIII
GeneF8 gene on X chromosome
InheritanceX-linked recessive
PathophysiologyImpaired intrinsic tenase activity and reduced thrombin generation
Clinical presentationHaemarthrosis, muscle haematomas and prolonged bleeding
PTNormal
aPTTOften prolonged
DiagnosisReduced factor VIII activity
Minor bleedingLocal measures; DDAVP in selected responsive mild cases
Major bleedingUrgent haemostatic therapy, commonly factor VIII replacement without inhibitors

10. Key Examination Pearls

  • Haemophilia A is caused by factor VIII deficiency.
  • It is an X-linked recessive disorder involving the F8 gene.
  • It commonly presents early in life with bleeding following trauma or surgery.
  • Haemarthrosis and muscle haematomas are characteristic.
  • Recurrent haemarthrosis may cause chronic joint damage.
  • PT and platelet count are normal, while aPTT is often prolonged.
  • Mild disease may have a normal aPTT.
  • Diagnosis is confirmed by reduced factor VIII activity.
  • Desmopressin may be effective for selected minor bleeding episodes in responsive mild haemophilia A.
  • Major bleeding generally requires prompt factor VIII replacement in patients without inhibitors.
  • Factor VIII inhibitors can complicate treatment.
  • Emicizumab is an important prophylactic option but is not used alone to treat acute major bleeding.
Most Important Examination Point

Haemophilia A is an X-linked factor VIII deficiency causing deep tissue and joint bleeding, with a typically prolonged aPTT and normal PT. Minor bleeding in selected mild cases may respond to desmopressin, whereas major bleeding requires urgent haemostatic therapy.

Clinical Note

Suspected serious bleeding, particularly intracranial, neck, abdominal or iliopsoas haemorrhage, requires urgent haemophilia specialist assessment and prompt haemostatic treatment. Treatment should be individualised according to disease severity, inhibitor status and available therapies.

Kembara Xtra – Medicine Revision Notes

Image description
0 Comments